MANGALAM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 8/100 — Quality 11 · Momentum 0
| Share price | ₹27.29 |
| Market cap | ₹44 Cr |
| P/B ratio | 0.4 |
| ROCE | -27.3% |
| Book value | ₹65.12 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹232 Cr | ₹-44 Cr | -6.0% |
| 2025 | ₹318 Cr | ₹7 Cr | 11.0% |
| 2024 | ₹369 Cr | ₹-9 Cr | 5.0% |
| 2023 | ₹366 Cr | ₹1 Cr | 4.0% |
| 2022 | — | — | — |
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetrapho